<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550589</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-046</org_study_id>
    <secondary_id>U01CA121947</secondary_id>
    <secondary_id>CDR0000570720</secondary_id>
    <nct_id>NCT00550589</nct_id>
  </id_info>
  <brief_title>Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus</brief_title>
  <official_title>Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused
      by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses
      and may stop these lesions from becoming cancer.

      PURPOSE: This phase II trial is studying the side effects and how well topical cidofovir
      works in treating HIV-infected patients with high-grade squamous intraepithelial lesions of
      the skin near the anus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the safety and tolerability of topical cidofovir in HIV-infected patients
           with perianal high-grade squamous intraepithelial lesions (HSIL).

        -  To estimate the regression rate of perianal HSIL in patients treated with this regimen.

      Secondary

        -  To determine the human papilloma virus (HPV) DNA types and HPV strain variants present
           in perianal HSIL and normal perianal tissue.

        -  To determine if clinical regression of perianal HSIL is associated with clearance of HPV
           DNA.

        -  To identify the HPV DNA types present in the anus and cervix and compare them with the
           HPV DNA present in the perianus in order to determine if the HPV types associated with
           the perianal lesions are the same as those infecting the anus and cervix.

        -  To determine if there are abnormally methylated genes in perianal HSIL compared with
           normal perianal tissue and if these genes are the same or different from those that have
           been previously identified in anal and cervical dysplasia.

        -  To determine whether methylated genes are changed after treatment with cidofovir.

        -  To characterize differences in gene expression in perianal HSIL compared with normal
           perianal tissue.

        -  To examine changes in gene expression in perianal HSIL after exposure to cidofovir using
           RNA microarray analysis and confirm results with real-time polymerase chain reaction.

        -  To correlate pretreatment CD4 count, viral load, lesion size, methylation pattern,
           and/or HPV type and strain with the clinical efficacy of topical cidofovir.

      OUTLINE: This is a multicenter study.

      Patients apply topical cidofovir to the perianus once daily on days 1-5. Patients undergo
      punch biopsy of pretreatment lesional biopsy sites on day 14. Beginning 2-4 weeks after
      biopsy, patients receive course 2 of cidofovir therapy. Subsequent treatment repeats every 14
      days for up to 6 courses* in the absence of disease progression or unacceptable toxicity.

      NOTE: *Patients receive a total of 6 courses of study therapy.

      Patients undergo collection of tumor and normal tissue for histopathological and molecular
      correlative studies. Punch biopsies are obtained at baseline, after the first course of
      therapy, and at 6 weeks after completion of therapy. Tissue samples are examined for
      histopathology, human papilloma virus (HPV)DNA typing, DNA methylation, and gene expression
      (via RNA microarray analysis and polymerase chain reaction).

      After completion of study therapy, patients are followed at 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)</measure>
    <time_frame>6 weeks after treatment discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0</measure>
    <time_frame>Every 2 weeks on study, 6 weeks after treatment discontinuation</time_frame>
    <description>Number of study patients who had a serious adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human Papilloma Virus (HPV) DNA Type in Perianal HSIL and Normal Perianal Tissue</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of patients with HPV16 at baseline in perianal HSIL and normal perianal tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Clinical Regression of Perianal HSIL With Clearance of HPV DNA</measure>
    <time_frame>6 weeks after treatment discontinuation</time_frame>
    <description>Number of patients who cleared HPV among those who had a complete or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of HPV-DNA Types Present in the Anus</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of patients with HPV16 type present in the anus from anal swab or cytobrush at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of Abnormally Methylated Genes in Perianal Dysplasia</measure>
    <time_frame>Baseline, after cycle 1, and 6 weeks after treatment discontinuation</time_frame>
    <description>Identification of abnormally methylated genes in perianal dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Abnormally Methylated Genes Among HSIL, Low-grade Squamous Intraepithelial Lesions, and Normal Perianal Skin</measure>
    <time_frame>Baseline, after cycle 1, and 6 weeks after treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis</measure>
    <time_frame>Baseline, after cycle 1, and 6 weeks after treatment discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Cidofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0% topical cidofovir cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cidofovir</intervention_name>
    <description>1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
    <description>formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>histopathologic examination</intervention_name>
    <description>Evaluated at baseline and 6 weeks after treatment discontinuation</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed perianal high-grade squamous intraepithelial lesions (HSIL)
             within the past 12 weeks

               -  The perianal skin (i.e., perianus) is defined as extending radially 5 cm from the
                  anal verge

               -  Lesions must cover a surface area of ≥ 3 square centimeters

               -  Lesions extending outside the perianus (e.g., vulvar lesions on the posterior
                  perineum bordering the perianus) are allowed

          -  Serologic documentation of HIV infection AND meets 1 of the following criteria:

               -  Has been on stable highly active anti-retroviral therapy (HAART) for ≥ 12 weeks
                  prior to study entry

               -  Has a CD4 count of &gt; 200/mm³ AND is not receiving anti-retroviral therapy OR is
                  currently receiving a non-HAART* anti-retroviral regimen with no plans to
                  initiate HAART within the next 12 weeks NOTE: * A non-HAART regimen is considered
                  to be a therapy that does not include a protease inhibitor or a non-nucleoside
                  reverse transcriptase inhibitor

          -  No untreated invasive cancer of the lower genital tract

          -  No concurrent neoplasia requiring cytotoxic therapy

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Life expectancy ≥ 3 months

          -  Hemoglobin ≥ 8 g/dL

          -  ANC ≥ 1,000/mm³

          -  Platelet count ≥ 75,000/mm³

          -  Creatinine &lt; 1.5 times upper limit of normal (ULN)

          -  Total or conjugated (direct) bilirubin ≤ 2.5 times ULN

          -  AST and ALT ≤ 3 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study therapy

          -  No acute, opportunistic infection other than oral thrush, yeast vaginitis, or genital
             herpes within the past 14 days

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior ablative or surgical treatment of perianal dysplasia

          -  At least 4 weeks since prior topical treatment for perianal dysplasia

               -  If any prior treatment caused significant trauma to ther area, healing should
                  occur prior to starting treatment

          -  More than 14 days since prior acute treatment for infection (other than for oral
             thrush, yeast vaginitis, or genital herpes) or other serious medical illness

          -  No concurrent corticosteroids other than replacement doses

          -  No other concurrent investigational drugs except IND-approved anti-retroviral agents

          -  No concurrent systemic cytotoxic chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Stier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Palefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Clinical AIDS Research and Education (CARE) Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Surgery Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, Lee JY, Darragh TM, Da Costa M, Panther L, Aboulafia D, Palefsky JM. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS. 2013 Feb 20;27(4):545-51. doi: 10.1097/QAD.0b013e32835a9b16.</citation>
    <PMID>23032420</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <results_first_submitted>May 24, 2011</results_first_submitted>
  <results_first_submitted_qc>May 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2011</results_first_posted>
  <disposition_first_submitted>May 10, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>May 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 23, 2011</disposition_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-grade squamous intraepithelial lesion</keyword>
  <keyword>stage 0 anal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cidofovir</title>
          <description>1.0% topical cidofovir cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cidofovir</title>
          <description>1.0% topical cidofovir cream</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)</title>
        <time_frame>6 weeks after treatment discontinuation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)</title>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0</title>
        <description>Number of study patients who had a serious adverse event</description>
        <time_frame>Every 2 weeks on study, 6 weeks after treatment discontinuation</time_frame>
        <population>All enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1% cidofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0</title>
          <description>Number of study patients who had a serious adverse event</description>
          <population>All enrolled patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Papilloma Virus (HPV) DNA Type in Perianal HSIL and Normal Perianal Tissue</title>
        <description>Number of patients with HPV16 at baseline in perianal HSIL and normal perianal tissue</description>
        <time_frame>Baseline</time_frame>
        <population>Number of patients with tissue samples available at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream</description>
          </group>
        </group_list>
        <measure>
          <title>Human Papilloma Virus (HPV) DNA Type in Perianal HSIL and Normal Perianal Tissue</title>
          <description>Number of patients with HPV16 at baseline in perianal HSIL and normal perianal tissue</description>
          <population>Number of patients with tissue samples available at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Clinical Regression of Perianal HSIL With Clearance of HPV DNA</title>
        <description>Number of patients who cleared HPV among those who had a complete or partial response</description>
        <time_frame>6 weeks after treatment discontinuation</time_frame>
        <population>Participants who had a partial or complete response and for whom pre and post-treatment HPV data were available</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream
cidofovir: 1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
DNA methylation analysis: formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
gene expression analysis: punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
polymerase chain reaction: performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
biopsy: punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
histopathologic examination: Evaluated at baseline and 6 weeks after treatment discontinuation</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Clinical Regression of Perianal HSIL With Clearance of HPV DNA</title>
          <description>Number of patients who cleared HPV among those who had a complete or partial response</description>
          <population>Participants who had a partial or complete response and for whom pre and post-treatment HPV data were available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identification of HPV-DNA Types Present in the Anus</title>
        <description>Number of patients with HPV16 type present in the anus from anal swab or cytobrush at baseline</description>
        <time_frame>Baseline</time_frame>
        <population>Number of patients with anal swabs or cytobrush results at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream</description>
          </group>
        </group_list>
        <measure>
          <title>Identification of HPV-DNA Types Present in the Anus</title>
          <description>Number of patients with HPV16 type present in the anus from anal swab or cytobrush at baseline</description>
          <population>Number of patients with anal swabs or cytobrush results at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identification of Abnormally Methylated Genes in Perianal Dysplasia</title>
        <description>Identification of abnormally methylated genes in perianal dysplasia</description>
        <time_frame>Baseline, after cycle 1, and 6 weeks after treatment discontinuation</time_frame>
        <population>The lab analysis of genes was not performed</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream</description>
          </group>
        </group_list>
        <measure>
          <title>Identification of Abnormally Methylated Genes in Perianal Dysplasia</title>
          <description>Identification of abnormally methylated genes in perianal dysplasia</description>
          <population>The lab analysis of genes was not performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Abnormally Methylated Genes Among HSIL, Low-grade Squamous Intraepithelial Lesions, and Normal Perianal Skin</title>
        <time_frame>Baseline, after cycle 1, and 6 weeks after treatment discontinuation</time_frame>
        <population>The gene analysis was not done</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Abnormally Methylated Genes Among HSIL, Low-grade Squamous Intraepithelial Lesions, and Normal Perianal Skin</title>
          <population>The gene analysis was not done</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis</title>
        <time_frame>Baseline, after cycle 1, and 6 weeks after treatment discontinuation</time_frame>
        <population>The gene expression analysis was not done</population>
        <group_list>
          <group group_id="O1">
            <title>Cidofovir</title>
            <description>1.0% topical cidofovir cream</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis</title>
          <population>The gene expression analysis was not done</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cidofovir</title>
          <description>1.0% topical cidofovir cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Anus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemorrhage, other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Rectum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain, anus</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain, other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain, perineum</sub_title>
                <counts group_id="E1" events="49" subjects_affected="14" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Infection, lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Infection, upper airway</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Infection, vagina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Infection, skin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST,SGOT Elevation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Metabolic, other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pulmonary, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/skin</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="30" subjects_affected="17" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeannette Lee</name_or_title>
      <organization>Statistical Center of AIDS Malignancy Consortium</organization>
      <phone>(501) 526-6712</phone>
      <email>jylee@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

